Literature DB >> 17846304

Outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with drug-eluting stents for patients with multivessel coronary artery disease.

Aamir Javaid1, Daniel H Steinberg, Ashesh N Buch, Paul J Corso, Steven W Boyce, Tina L Pinto Slottow, Probal K Roy, Peter Hill, Teruo Okabe, Rebecca Torguson, Kimberly A Smith, Zhenyi Xue, Natalie Gevorkian, William O Suddath, Kenneth M Kent, Lowell F Satler, Augusto D Pichard, Ron Waksman.   

Abstract

BACKGROUND: Advances in coronary artery bypass grafting (CABG) surgery and percutaneous coronary intervention (PCI) with drug-eluting stents have dramatically improved results of these procedures. The optimal treatment for patients with multivessel coronary artery disease is uncertain given the lack of prospective, randomized data reflecting current practice. This study represents a "real-world" evaluation of current technology in the treatment of multivessel coronary artery disease. METHODS AND
RESULTS: A total of 1680 patients undergoing revascularization for multivessel coronary artery disease were identified. Of these, 1080 patients were treated for 2-vessel disease (196 CABG and 884 PCI) and 600 for 3-vessel disease (505 CABG and 95 PCI). One-year mortality, cerebrovascular events, Q-wave myocardial infarction, target vessel failure, and composite major adverse cardiovascular and cerebrovascular events were compared between the CABG and PCI cohorts. Outcomes were adjusted for baseline covariates and reported as hazard ratios. The unadjusted major adverse cardiovascular and cerebrovascular event rate was reduced with CABG for patients with 2-vessel disease (9.7% CABG versus 21.2% PCI; P<0.001) and 3-vessel disease (10.8% CABG versus 28.4% PCI; P<0.001). Adjusted outcomes showed increased major adverse cardiovascular and cerebrovascular event with PCI for patients with 2-vessel (hazard ratio 2.29; 95% CI 1.39 to 3.76; P=0.01) and 3-vessel disease (hazard ratio 2.90; 95% CI 1.76 to 4.78; P<0.001). Adjusted outcomes for the nondiabetic subpopulation demonstrated equivalent major adverse cardiovascular and cerebrovascular event with PCI for 2-vessel (hazard ratio 1.77; 95% CI 0.96 to 3.25; P=0.07) and 3-vessel disease (hazard ratio 1.70; 95% CI 0.77 to 3.61; P=0.19).
CONCLUSIONS: Compared with PCI with drug-eluting stents, CABG resulted in improved major adverse cardiovascular and cerebrovascular event in patients with 2- and 3-vessel coronary artery disease, primarily in those with underlying diabetes. Coronary artery bypass surgery may be the preferred revascularization strategy in diabetic patients with multivessel coronary artery disease.

Entities:  

Mesh:

Year:  2007        PMID: 17846304     DOI: 10.1161/CIRCULATIONAHA.106.681148

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  26 in total

1.  Surgical ineligibility and mortality among patients with unprotected left main or multivessel coronary artery disease undergoing percutaneous coronary intervention.

Authors:  Stephen W Waldo; Eric A Secemsky; Cashel O'Brien; Kevin F Kennedy; Eugene Pomerantsev; Thoralf M Sundt; Edward J McNulty; Benjamin M Scirica; Robert W Yeh
Journal:  Circulation       Date:  2014-11-12       Impact factor: 29.690

2.  [Modern coronary surgery, the SYNTAX trial and updated guidelines].

Authors:  A Thiem; T Attmann; J Cremer
Journal:  Herz       Date:  2011-12       Impact factor: 1.443

3.  SYNTAX-justified trend toward restricting coronary artery bypass grafting to more serious cases.

Authors:  Mamoru Arakawa; Atsushi Yamaguchi; Kenichi Sakakura; Homare Okamura; Junya Ako; Shin-Ichi Momomura; Hideo Adachi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-12-15

4.  Long-term mortality of coronary artery bypass grafting and bare-metal stenting.

Authors:  Chuntao Wu; Songyang Zhao; Andrew S Wechsler; Stephen Lahey; Gary Walford; Alfred T Culliford; Jeffrey P Gold; Craig R Smith; David R Holmes; Spencer B King; Robert S D Higgins; Desmond Jordan; Edward L Hannan
Journal:  Ann Thorac Surg       Date:  2011-10-19       Impact factor: 4.330

Review 5.  The comparative efficacy of percutaneous and surgical coronary revascularization in 2009: a review.

Authors:  Stephen A May; James M Wilson
Journal:  Tex Heart Inst J       Date:  2009

6.  Further opportunities for cost reduction of medical care.

Authors:  M Malach; W J Baumol
Journal:  J Community Health       Date:  2010-12

7.  Coronary revascularization in diabetic patients: Current state of evidence.

Authors:  Mukesh Singh; Rohit Arora; Vamsi Kodumuri; Sandeep Khosla; Evyan Jawad
Journal:  Exp Clin Cardiol       Date:  2011

Review 8.  Stenting versus surgery for significant left main disease.

Authors:  Ralf E Harskamp; Duk-Woo Park
Journal:  Curr Cardiol Rep       Date:  2015       Impact factor: 2.931

9.  Composite outcomes in coronary bypass surgery versus percutaneous intervention.

Authors:  Fred H Edwards; David M Shahian; Maria V Grau-Sepulveda; Frederick L Grover; John E Mayer; Sean M O'Brien; Elizabeth DeLong; Eric D Peterson; Charles McKay; Richard E Shaw; Kirk N Garratt; George D Dangas; John Messenger; Lloyd W Klein; Jeffrey J Popma; William S Weintraub
Journal:  Ann Thorac Surg       Date:  2014-04-26       Impact factor: 4.330

10.  Translating basic behavioral and social science research to clinical application: the EVOLVE mixed methods approach.

Authors:  Janey C Peterson; Susan Czajkowski; Mary E Charlson; Alissa R Link; Martin T Wells; Alice M Isen; Carol A Mancuso; John P Allegrante; Carla Boutin-Foster; Gbenga Ogedegbe; Jared B Jobe
Journal:  J Consult Clin Psychol       Date:  2012-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.